Delivery Order SPE2DB20D3101-SPE2DB25FRBJ2

Award Date 2/7/25
Potential Completion Date 2/10/25
Potential Value $3.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4 mg ondansetron orally disintegrating tablets. The contract has a ceiling value of $3,482.29 and a performance period that runs through January 22, 2025. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. The IDC serves as a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4 mg Ondansetron Hydrochloride tablets. The contract has a firm fixed price, with a total ceiling value of $11,378.79, and runs through June 3, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of ondansetron hydrochloride 4 mg tablets. The delivery order, valued at $6,252.47, has an ultimate completion date of September 3, 2024 and was awarded on August 30, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4 mg ondansetron hydrochloride tablets. The contract has a firm fixed price of $21,051.92 and a period of performance through May 31, 2023. This award is a child contract under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 8 mg ondansetron hydrochloride tablets. The contract has a ceiling value of $22,599.92 and an ultimate completion date of December 4, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4 mg Ondansetron HCL tablets. The contract has a firm fixed price of $19,212.66 and an ultimate completion date of February 18, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical worth $999,999,999 through November 2026, which serves as the primary vehicle for providing a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide 4,567,331,507 units of 8 mg Ondansetron hydrochloride tablets. The contract has a ceiling value of $9,265.41 and a period of performance through February 21, 2025. It is a firm fixed-price contract, with no set-aside designation noted. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical under an Indefinite Delivery Contract (IDC) valued at $999,999,999. The order is for 4,561,076,878 units of the prescription drug Ondansetron ODT 4 mg Tablet, at a ceiling value of $1,041.90. The contract is a firm fixed-price delivery order with a completion date of May 31, 2023. The contract award was not designated with a set-aside....
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $1,865.48 firm fixed-price delivery order is for the supply of 4 mg ondansetron HCL tablets. The contract has an ultimate completion date of January 27, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This is a delivery order awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) under an Indefinite Delivery Contract (IDC) valued at $999,999,999. The contract is for the supply of 4560732432 - Ondansetron ODT 4 mg tablets in 30-count packages, with a ceiling value of $3,198.00 and a completion date of April 27, 2023. This delivery order is part of a broader IDC that provides a comprehensive range of pharmaceutical products and...
  • SPE2DB20D3101
    Indefinite Delivery Contract
  • SPE2DB20D3101-SPE2DB25FRBJ2
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4 milligram ondansetron hydrochloride tablets. The delivery order has a ceiling value of $3,615.57 and a completion date of February 10, 2025. It is placed under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/21/25, 9:50 AM